Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
NCT06567743
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
325
Enrollment
INDUSTRY
Sponsor class
Conditions
High-Risk Non-Muscle-Invasive Bladder Cancer
Interventions
DRUG:
Cretostimogene Grenadenorepvec
Sponsor
CG Oncology, Inc.